Order Article Reprints

Yamada T, Nagasaka T, Matsuhashi N, Takahashi T, Hirata K, Nakamura Y, Sugimoto K, Koda K, Hiramatsu K, Matsuoka H, et al. Clinical Impact of Baseline ctDNA RAS/BRAF Mutations on Conversion Surgery and Outcomes in First-Line Anti-EGFR Therapy for Advanced Colorectal Cancer. Cancers. 2026; 18(11):1688. https://doi.org/10.3390/cancers18111688

Yamada, Takeshi, Takeshi Nagasaka, Nobuhisa Matsuhashi, Takao Takahashi, Keiji Hirata, Yuki Nakamura, Kiichi Sugimoto, Keiji Koda, Kazuhiro Hiramatsu, Hiroshi Matsuoka, and et al. 2026. "Clinical Impact of Baseline ctDNA RAS/BRAF Mutations on Conversion Surgery and Outcomes in First-Line Anti-EGFR Therapy for Advanced Colorectal Cancer" Cancers 18, no. 11: 1688. https://doi.org/10.3390/cancers18111688

Yamada, T., Nagasaka, T., Matsuhashi, N., Takahashi, T., Hirata, K., Nakamura, Y., Sugimoto, K., Koda, K., Hiramatsu, K., Matsuoka, H., Kuramochi, H., Matsuda, A., Ishida, H., Kataoka, K., Yokomizo, H., Kagawa, Y., Suenaga, M., & Yoshida, H. (2026). Clinical Impact of Baseline ctDNA RAS/BRAF Mutations on Conversion Surgery and Outcomes in First-Line Anti-EGFR Therapy for Advanced Colorectal Cancer. Cancers, 18(11), 1688. https://doi.org/10.3390/cancers18111688